Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyrroloquinoline quinone (PQQ) disodium is a salt form of the redox-active cofactor PQQ, which is being investigated for its potential anti-aging and neuroprotective properties. It acts as a cofactor for several enzymes and is known to stimulate mitochondrial biogenesis, primarily through the activation of the PGC-1α pathway and modulation of Sirtuin 1 (Sirt1). In clinical research, such as the study conducted by The First People's Hospital of Kunshan (ChiCTR2500103910), PQQ disodium is evaluated for its ability to increase NAD+ levels, enhance antioxidant defenses by increasing superoxide dismutase (SOD) activity, and reduce oxidative damage as measured by malondialdehyde (MDA) levels. It is commonly available as a dietary supplement and is studied for its effects on fatigue and cognitive function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pyrroloquinoline quinone disodium.